Latuda contains lurasidone, which is a 2nd generation antipsychotic authorised for the treatment of schizophrenia in adults aged 18 years and over.
Lurasidone efficacy in the PANSS total score is on a par with other 2nd generation antipsychotics, but has been demonstrated to be different from the other antipsychotics by having increased effect on cognitive symptoms. However, it is still too early to draw any conclusions about a possible improvement of cognitive performance since lurasidone's effect on cognitive symptoms has only been investigated on a small data set and with ziprasidone and quetiapine as the only active comparators.
The clinical studies found that lurasidone had none or minimal effect on body weight compared to placebo, which otherwise is only the case with ziprasidone and halopedidol. In addition, there are minimal effects on metabolic parameters as well as the QT interval.
A line of antipsychotics with a similar efficacy profile are already sold on the market as generic products, which makes them significantly cheaper than Latuda.
It is IRF's overall assessment that Latuda should not be a first-line treatment for schizophrenia in adults, but it could be relevant in cases where the minimisation of metabolic and cardiovascular effects is of utmost importance or in patients who are extremely concerned about gaining weight.
Latuda was marketed on 15 September 2014.
Presently, general conditional reimbursement is granted for Latuda provided the following condition is satisfied:
Patients for whom treatment with antipsychotics with general unconditional reimbursement is inadequate or is not tolerated, or currently/previously successfully treated patients for whom it would be inappropriate – based on the doctor's overall clinical assessment of the patient's mental condition – to treat with or a switch to an antipsychotic with general unconditional reimbursement.